Scientific Publications

Home OCT & Notal OCT Analyzer
November 18, 2024

Artificial intelligence in assessing progression of age-related macular degeneration

Frank-Publig, S., Birner, K., Riedl, S. et al. Artificial intelligence in assessing progression of age-related macular degeneration. Eye (2024). https://doi.org/10.1038/s41433...

November 8, 2024

Home OCT and Sustained Delivery Approaches, a Perfect Marriage

Holekamp, Nancy M.; N1 - DOI: 10.1016/j.ajo.2024.10.031 | American Journal of Ophthalmology. https://www.ajo.com/article/S0002-9394(24)00512-9/abstract

May 2024

Prospective Trial of Home OCT Guided Management of Treatment Experienced nAMD Patients

Holekamp, Nancy M. MD; de Beus, Anthony M.; Clark, W. Lloyd; Heier, Jeffrey S. MD. Prospective trial of Home OCT guided management of treatment experienced nAMD patients. Retina The Journal of Retinal and Vitreous Diseases: 10.1097/IAE.0000000000004167, May 22, 2024. | DOI: 10.1097/IAE.0000000000004167 https://journals.lww.com/retin...

October 2023

Home Optical Coherence Tomography Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study

Blinder KJ, Calhoun C, Maguire MG, Glassman AR, Mein CE, Baskin DE, Vieyra G, Jampol LM, Chica MA, Sun JK, Martin DF; DRCR Retina Network. Home Optical Coherence Tomography Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study. Ophthalmol Retina. 2023 Oct 23:S2468-6530(23)00514-6. doi: 10.1016/j.oret.2023.10.012. Epub ahead of print. PMID: 37879537. https://pubmed.ncbi.nlm.nih.go...

October 2023

The Impact of Artificial Intelligence on Retinal Disease Management

Carla Danese; Aditya U. Kale; Tariq Aslam; Paolo Lanzetta; Jane Barratt; Yu-Bai Chou; Bora Eldem; Nicole Eter; Richard Gale; Jean-François Korobelnik; Igor Kozak; Xiaorong Li; Xiaoxin Li; Anat Loewenstein; Paisan Ruamviboonsuk; Taiji Sakamoto; Daniel S.W. Ting; Peter van Wijngaarden; Sebastian M. Waldstein; David Wong; Lihteh Wu; Miguel A. Zapata; Javier Zarranz-Ventura. DISCLOSURES | Curr Opin Ophthalmol. 2023;34(5):396-402. https://www.medscape.com/s/vie...


See Home OCT & Notal OCT Analyzer presentations

SCANLY Home OCT FDA Intended Use

SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.

See also Warnings and Precautions.

ForeseeHome FDA Intended Use

ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

Media enquiries? Reach out to our Media Contact